Inventiva S.A. (LON:0RNK)
London · Delayed Price · Currency is GBP · Price in EUR 2.880
0.00 (0.00%)
At close: Aug 7, 2025
Lions Gate Entertainment Revenue
In the year 2024, Inventiva had annual revenue of 14.09M EUR, down -38.24%. Inventiva had revenue of 11.36M in the half year ending December 31, 2024, a decrease of -26.34%.
Revenue
14.09M EUR
Revenue Growth
-38.24%
P/S Ratio
29.70
Revenue / Employee
119.44K EUR
Employees
118
Market Cap
346.14M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
| Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
| Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Oxford Nanopore Technologies | 183.19M |
Inventiva News
- 4 weeks ago - Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance - GlobeNewsWire
- 4 weeks ago - Inventiva receives $10 million milestone payment from CTTQ - GlobeNewsWire
- 5 weeks ago - Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease - GlobeNewsWire
- 2 months ago - Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference - GlobeNewsWire
- 2 months ago - Inventiva S.A. reports Q1 results - Seeking Alpha
- 2 months ago - Inventiva reports 2025 First Quarter Financial Information¹ - GlobeNewsWire
- 2 months ago - Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 - Benzinga
- 2 months ago - Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 - GlobeNewsWire